Dishman close to deal with AstraZeneca, Merck-source
MUMBAI (Reuters) - Dishman Pharmaceuticals & Chemicals Ltd is close to signing contracts with U.S. Merck & Co Inc and AstraZeneca for supplying bulk drugs, a source close to the deal said on Tuesday.
"The contracts are expected to be signed in a month's time," the source, who declined to be named told Reuters.
Dishman already has a long-term contract manufacturing deal with Dutch Solvay for supplying bulk drugs and intermediates.
Global pharmaceutical giants are increasingly outsourcing drug manufacturing to companies in India as they seek to benefit from lower manufacturing costs here.
© Thomson Reuters 2009 All rights reserved
India Investment Summit 2009
Top executives and bankers discuss their own plans and the broader opportunities and challenges for India during the Reuters India Investment Summit in Mumbai and Bangalore. Full Coverage | Blog
PLAYBOY SALE
An icon bows to changing times
With his Playboy Enterprises in talks to be sold for about $300 million, the 83 year-old Hugh Hefner will be giving up control over the iconic adult entertainment empire he founded that was instrumental in shaping society's opinions on nudity, sex and free speech. Full Article
India
US
UK
